Pneumocystis Jirovecii Pneumonia
Also written as PJP, PCP.
*Silver stain (e.g., GMS) demonstrating cyst-like organisms in alveoli in an immunocompromised (especially HIV/AIDS) patient is classic for Pneumocystis jirovecii pneumonia (PJP).*
What our notes say
- *Silver stain (e.g., GMS) demonstrating cyst-like organisms in alveoli in an immunocompromised (especially HIV/AIDS) patient is classic for Pneumocystis jirovecii pneumonia (PJP).* (End Sem Cat: Respiratory Pathology: Emphysema, ARDS, Pneumoconiosis)
- At what CD4 count is prophylaxis against *Pneumocystis jirovecii* pneumonia (PCP) typically initiated? → CD4 < 200 cells/µL (Antifungals, Antivirals, Antihelminthics & Antiprotozoals)
- Infections: - Early (within first 3 months): Bacterial infections are most common. - Later (3–12 months): Cytomegalovirus (CMV), fungal infections (Aspergillus, Candida), and Pneumocystis jirovecii pneumonia (PJP) are more prevalent. (Endocrine & Renal Pathology — Must Know Notes)
- Opportunistic infections (e.g., Pneumocystis jirovecii pneumonia, disseminated BCG/candidiasis) — due to absent T-cell surveillance against intracellular/opportunistic organisms (Immunopathology Exam: SCID, Transplant Rejection & GVHD)
- CD4 <200 – Pneumocystis jirovecii pneumonia (PCP) → prophylaxis/treatment with TMP-SMX (Pharmacology CRASH Course)
- | PCP treatment + prophylaxis | Pneumocystis jirovecii pneumonia — high-dose IV treatment; prophylaxis when CD4 <200 in HIV | (Pharmco Notes)